Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

ClinicalTrials.gov ID: NCT01515189

Public ClinicalTrials.gov record NCT01515189. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma

Study identification

NCT ID
NCT01515189
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
831 participants

Conditions and interventions

Conditions

Interventions

  • Ipilimumab Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 16, 2012
Primary completion
Feb 5, 2016
Completion
Aug 16, 2017
Last update posted
Jul 30, 2019

2012 – 2017

United States locations

U.S. sites
11
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
The Angeles Clinic And Research Institute Los Angeles California 90025
University Of California Los Angeles Los Angeles California 90095
Baptist Cancer Institute Jacksonville Florida 32207
Orlando Health, Inc Orlando Florida 32806
Oncology Specialists, S.C. Park Ridge Illinois 60068
Memorial Sloan Kettering Cancer Center New York New York 10065
Levine Cancer Institute Charlotte North Carolina 28204
Duke University Hospital Durham North Carolina 27710
Providence Portland Medical Center Portland Oregon 97213
St. Luke's Cancer Center - Anderson Campus Easton Pennsylvania 18045
Seattle Cancer Care Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01515189, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2019 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01515189 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →